Drug Profile


Latest Information Update: 19 Apr 1996

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nattermann
  • Developer Nonindustrial source
  • Class Antiulcers; Choleretics; Cholic acids; Cytoprotectives; Gallstone therapies; Glycerophospholipids; Lipids; Phosphatidylcholines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 19 Apr 1996 A clinical study has been added
  • 11 Jul 1995 A clinical study has been added to the therapeutic trials section .
  • 21 Feb 1995 Discontinued-II for Atherosclerosis in Russia (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top